Kepler Capital Markets Increases AstraZeneca plc (AZN) Price Target to GBX 5,250
AstraZeneca plc (LON:AZN) had its price target upped by investment analysts at Kepler Capital Markets from GBX 5,200 ($68.62) to GBX 5,250 ($69.28) in a report released on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Kepler Capital Markets’ price target would suggest a potential upside of 4.33% from the stock’s current price.
Several other brokerages have also recently issued reports on AZN. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Liberum Capital restated a “buy” rating and issued a GBX 5,500 ($72.58) price objective on shares of AstraZeneca plc in a research note on Thursday, July 13th. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, July 13th. Citigroup Inc. restated a “buy” rating and issued a GBX 6,000 ($79.18) price objective on shares of AstraZeneca plc in a research note on Thursday, July 13th. Finally, Morgan Stanley set a GBX 4,700 ($62.02) price objective on AstraZeneca plc and gave the stock a “neutral” rating in a research note on Friday, October 20th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. AstraZeneca plc presently has an average rating of “Hold” and an average price target of GBX 5,174.91 ($68.29).
AstraZeneca plc (LON:AZN) opened at 5107.00 on Wednesday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The stock’s market cap is GBX 64.65 billion. The stock has a 50 day moving average price of GBX 5,004.38 and a 200 day moving average price of GBX 4,928.31.
TRADEMARK VIOLATION WARNING: This piece was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://theolympiareport.com/2017/11/01/kepler-capital-markets-increases-astrazeneca-plc-azn-price-target-to-gbx-5250.html.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.